Femasys Inc. (NASDAQ:FEMY) Stock Short Interest Falls 70.0%

Femasys Inc. (NASDAQ:FEMY) saw a large drop in short interest in October. As of October 30th, there was short interest totaling 49,266 shares, a drop of 70.0% from the October 15th total of 164,106 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 100,794 shares, the short-interest ratio is presently 0.5 days.

Femasys Trading Up 1.4%

Femasys stock traded up $0.02 during trading hours on Friday, reaching $1.42. The company had a trading volume of 52,887 shares, compared to its average volume of 251,829. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.14 and a quick ratio of 0.55. Femasys has a 12-month low of $1.25 and a 12-month high of $20.80. The company has a 50-day moving average price of $1.99 and a 200 day moving average price of $5.67. The firm has a market cap of $11.90 million, a price-to-earnings ratio of -0.40 and a beta of -2.13.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.07. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.62 million.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wall Street Zen downgraded Femasys from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. Maxim Group reduced their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Lake Street Capital decreased their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Finally, Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Femasys Company Profile

Femasys Inc. is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures. Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.